2026-07-22T07:49:20Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/226572024-11-28T20:11:01Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967col_20.500.12105_16985col_20.500.12105_16989
Repisalud author Lopez-Sainz, Angela author Climent, Vicente author Ripoll-Vera, Tomás author Angeles Espinosa, Maria author Barriales-Villa, Roberto author Navarro, Marina author Limeres, Javier author Domingo, Diana author Kasper, David C author Garcia-Pavia, Pablo 2024-09-10T13:06:53Z 2024-09-10T13:06:53Z 2019-07-08 Lopez-Sainz A, Climent V, Ripoll-Vera T, Espinosa MA, Barriales-Villa R, Navarro M, et al. D249 [letter]. Orphanet J Rare Dis. 2019 Jul 08;14.170. 10.1186/s13023-019-1140-3 1750-1172 Orphanet Journal of Rare Diseases http://hdl.handle.net/20.500.13003/15942 31286959 L628451879 2-s2.0-85068870122 https://hdl.handle.net/20.500.12105/22657 475683800001 Identification of Fabry disease (FD) in cardiac patients has been restricted so far to patients with left ventricular hypertrophy. Conduction problems are frequent in FD and could precede other manifestations, offering a possible earlier diagnosis.We studied the prevalence of FD in 188 patients <70years with conduction problems requiring pacemaker implantation. Although classical manifestations of FD were not rare, no patient with FD was identified. Screening efforts should not be conducted in this population. eng Fabry disease Conduction disease Pacemaker Left ventricular hypertrophy Screening Negative screening of Fabry disease in patients with conduction disorders requiring a pacemaker letter to the editor